Skip to content
Assyro AI
Orange Book drug · Brand (NDA)

Remodulin

Treprostinil

RLDNDA 021272 8 strengths United Therap
Approved
May 21, 2002
Strengths
8
Listed patents
5
Applications
2

What does the FDA Orange Book show for Remodulin?

Remodulin contains Treprostinil and appears in 2 FDA Orange Book applications. NDA 021272 is the lead filing, with 8 presentations shown in detail; the other exact-name filings are listed separately. The page preserves strength, dosage form, route, status, RLD/RS, TE, patent, and exclusivity facts. Clinical labeling requires an exact application-matched source.

FDA applications
2; lead NDA 021272

Every filing shown uses the exact FDA product name; the lead filing supplies the detailed presentation view.

Lead application holder
United Therapeutics Corp

The listed applicant holds the FDA application; this field does not establish the product manufacturer.

Product presentations
8

Each FDA product number remains tied to its own strength, dosage form, route, and status.

Marketing categories
Prescription and Discontinued

Orange Book marketing categories do not establish real-time inventory or commercial availability.

Reference roles
RLD / RS

RLD and RS designations are presentation-specific, not inferred from the trade name.

TE codes
AP

Therapeutic-equivalence codes apply only within the matching Orange Book product heading.

Listed patents
5

A zero means none appear in this snapshot, not that no patent rights exist.

Exclusivity records
0

FDA exclusivity and listed patent protection are distinct regulatory concepts.

Sourced from the official FDA Orange Book data file · snapshot refreshed

FDA product-presentation matrix

Every product number in this exact application
Every FDA product presentation under this application, with strength, dosage form and route, marketing status, therapeutic-equivalence code, and reference role.
ProductStrengthDosage form / routeMarketing statusTE codeReference role
0011MG/MLINJECTABLEINTRAVENOUS, SUBCUTANEOUSPrescriptionAP
RLDRS
0022.5MG/MLINJECTABLEINTRAVENOUS, SUBCUTANEOUSPrescriptionAP
RLDRS
0035MG/MLINJECTABLEINTRAVENOUS, SUBCUTANEOUSPrescriptionAP
RLDRS
00410MG/MLINJECTABLEINTRAVENOUS, SUBCUTANEOUSPrescriptionAP
RLDRS
00520MG/MLINJECTABLEINTRAVENOUS, SUBCUTANEOUSDiscontinuedNone posted
RLD
0060.1MG/MLINJECTABLEINTRAVENOUS, SUBCUTANEOUSDiscontinuedNone posted
RLD
0070.2MG/MLINJECTABLEINTRAVENOUS, SUBCUTANEOUSDiscontinuedNone posted
RLD
0080.4MG/MLINJECTABLEINTRAVENOUS, SUBCUTANEOUSPrescriptionNone posted
RLDRS

Marketing status, TE code, RLD, and RS are presentation-level fields. Never transfer one product number's designation to another presentation.

Who is responsible for this application?

Application holder is not the same as manufacturer

FDA application holder

United Therapeutics Corp

The Orange Book identifies this organization as the applicant responsible for NDA 021272.

Manufacturer status

Not established by the Orange Book

A product-specific FDA label or NDC source must independently identify a manufacturer, labeler, distributor, packager, repackager, or relabeler. The applicant name is not used as a substitute for that evidence.

Regulatory interpretation

What the record means, and what it does not
FDA marketing status

Status varies by presentation: 5 prescription and 3 on the Discontinued Drug Product List

Orange Book status is assigned at the product-presentation level, so one strength can remain listed as prescription or OTC while another appears on the discontinued list.

Therapeutic equivalence

TE code AP across rated presentations

An AP code is an A-rating: FDA considers the product therapeutically equivalent to pharmaceutical equivalents in the same Orange Book heading and equivalence group. 4 presentations in the application have no posted TE code.

Patent & exclusivity record

5 listed patent expirations and 0 exclusivity dates remain on or after Jul 26, 2026

The latest future date recorded across those files is Mar 29, 2029. Patent and FDA exclusivity operate independently, can overlap, and do not by themselves predict a generic launch date.

Same-ingredient landscape

5 other ANDAs and 2 other NDAs found

4 of the related ANDA applications are not marked discontinued. Sharing an ingredient does not establish pharmaceutical or therapeutic equivalence; strength, dosage form, route, and TE group still matter.

Which products are meaningfully comparable?

Exact ingredient + dosage form + route cohorts

NDA 021272 appears in 1 comparison cohort. These groups narrow the same-ingredient landscape, but strength and TE code must still match before interpreting therapeutic equivalence.

Why are clinical sections unavailable?

Exact application-label matching status
Exact source match queuedQueue NDA-021272

No exact application-level FDA or DailyMed label match has been reviewed for this application. Approved uses, dosing, warnings, adverse reactions, and clinical evidence remain unavailable rather than being inherited from a related brand, generic, or ingredient record.

Until an exact application match passes human review, this page intentionally omits approved uses, dosing, warnings, adverse reactions, mechanism, and clinical-study summaries. It never inherits those claims from an RLD, brand, generic, or same-ingredient product.

Strengths & dosage forms

8 approved presentations · NDA 021272
TE APRLDRS
Strength
1MG/ML
Dosage form
INJECTABLE
Route
INTRAVENOUS, SUBCUTANEOUS
Marketing status
Prescription

Key dates

Approval, patents, exclusivity

  1. Approval

    FDA approval date of this drug product.

    24 yr 6 mo ago

  2. Today

  3. Patent 8653137 expires

    Listed method-of-use patent (U-1437) expiration.

    in 2 yr 2 mo

  4. Patent 8658694 expires

    Listed method-of-use patent (U-1437) expiration.

    in 2 yr 2 mo

  5. Patent 11723887 expires

    Listed drug substance patent expiration.

    in 2 yr 5 mo

  6. Patent 9593066 expires

    Listed drug substance patent expiration.

    in 2 yr 5 mo

  7. Patent 7999007 expires

    Listed drug product patent expiration.

    in 2 yr 9 mo

Patent & exclusivity timeline

Protection horizon
20262027202820292030TodayPatent 8653137: 2028-09-05Patent 8653137Patent 8658694: 2028-09-05Patent 8658694Patent 11723887: 2028-12-15Patent 11723887Patent 9593066: 2028-12-15Patent 9593066Patent 7999007: 2029-03-29Patent 7999007
Patent expiryExclusivity endToday

Pharmaceutical detail

FDA product record

Active ingredient

TREPROSTINIL

Strength

1MG/ML

Dosage form

INJECTABLE

Route

INTRAVENOUS, SUBCUTANEOUS

TE code

AP

Application

NDA 021272

Product number

001

Marketing status

Prescription

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Listed patents

Orange Book patent file
Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
8653137in 2 yr 2 mo
U-1437
8658694in 2 yr 2 mo
U-1437
11723887in 2 yr 5 mo
Substance
9593066in 2 yr 5 mo
Substance
7999007in 2 yr 9 mo
ProductU-1437

Other FDA applications for Remodulin

1 additional filing

The FDA has approved 2 separate applications under this product name. Each row is one application: a distinct applicant and approval for the same drug.

Other FDA applications approved under the product name Remodulin, with applicant, approval date, number of strengths, therapeutic-equivalence code, and marketing status.
ApplicationApplicantApprovedStrengthsTE codeStatus
NDA 208276United TherapJul 30, 20184—Discontinued

Active-ingredient family

Brand + generics

This is a reference-listed drug (RLD), the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

View full Treprostinil family

How to use this record responsibly

Scope, limitations, and primary sources

What to verify before making a decision

  • The applicant is the holder of legal responsibility for the application; the Orange Book does not establish that the applicant manufactured or currently markets every listed product.
  • RX, OTC, and discontinued are FDA listing categories, not real-time pharmacy inventory or commercial-availability data.
  • Therapeutic equivalence applies only within the matching ingredient, dosage form, route, strength, and TE-code group; same ingredient alone is insufficient.
  • Listed patent and exclusivity dates are regulatory intelligence, not legal advice, a freedom-to-operate analysis, or a reliable generic-launch forecast.
  • The Orange Book is not prescribing information and does not provide indications, dosing, contraindications, adverse reactions, recalls, or current safety communications.

Official FDA references

Data shown here is normalized for search and comparison. When a regulatory, substitution, launch, or legal decision turns on a field, verify it against the current FDA record and the relevant source document.

Remodulin: frequently asked questions

Approval, therapeutic equivalence, patents, and exclusivity for this drug, from the FDA Orange Book.

Built directly from the FDA Orange Book product, patent, and exclusivity files refreshed Jul 02, 2026, 06:34 PM. Every strength of NDA 021272 is shown on this page. Interpret patents, exclusivity, availability, and therapeutic equivalence using the limitations above.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo